Stock listing
Pharmaessentia Corp.
Selected listing: PHECR · LUXSE · USD · LU
Pharmaessentia Corp. (LUXSE:PHECR), Health Technology. Latest release Sep 9, 2026: PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO)…
- Ticker
- LUXSE:PHECR
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LUXSE
- Currency
- USD
Latest news from Pharmaessentia Corp.
PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
September 9, 2026
FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer
August 31, 2026
PharmaEssentia Announces Health Canada Approval of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
July 7, 2026
PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)
July 6, 2026
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (ropeginterferon alfa-2b-njft) for Polycythemia Vera
June 29, 2026
Research Pharmaessentia Corp.
Pharmaessentia Corp. company profile
View the public company page for Pharmaessentia Corp. on 6ix.
Pharmaessentia Corp. news
Read company news and market updates connected to Pharmaessentia Corp..
Pharmaessentia Corp. investor events
Find investor webinars, events, and replay context for Pharmaessentia Corp..
Alternate listings
6446:TWSE
TW · TWD
Alternate listing for Pharmaessentia Corp.; the primary context on this page is PHECR:LUXSE.
8Z1:FWB
DE · EUR
Alternate listing for Pharmaessentia Corp.; the primary context on this page is PHECR:LUXSE.
PHECA:LUXSE
LU · USD
Alternate listing for Pharmaessentia Corp.; the primary context on this page is PHECR:LUXSE.